## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. REG - AstraZeneca PLC - Subcutaneous Saphnelo approved in EU**
- Source: TradingView â€” Track All Markets | 20251217T000952 | Bullish | Relevance: 100%
- AstraZeneca's Saphnelo (anifrolumab) has received EU approval for subcutaneous self-administration as a pre-filled pen for adult systemic lupus erythematosus (SLE) patients. This approval, based on the Phase III TULIP-SC trial, offers a convenient at-home treatment option with the same clinical benefits as the intravenous infusion. The new formulation aims to broaden patient access to this important medicine, especially since many SLE patients on biologics prefer subcutaneous self-administration.

**2. AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen**
- Source: Benzinga | 20251216T171052 | Bullish | Relevance: 100%
- AstraZeneca (NASDAQ: AZN) received FDA approval for Enhertu, in combination with pertuzumab, for first-line treatment of HER2-positive breast cancer, based on positive DESTINY-Breast09 trial results. This approval triggers a $150 million milestone payment to Daiichi Sankyo. Additionally, the European Commission approved AstraZeneca's Saphnelo for subcutaneous self-administration in systemic lupus erythematosus, with AstraZeneca paying a royalty to Bristol-Myers Squibb & Co (NYSE: BMY) on sales.

**3. AstraZeneca PLC - Enhertu approved in US for 1L HER2+ metastatic BC**
- Source: Research Tree | 20251216T121052 | Bullish | Relevance: 100%
- AstraZeneca and Daiichi Sankyo's Enhertu, in combination with pertuzumab, has received US FDA approval for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. This approval, based on the DESTINY-Breast09 Phase III trial, marks the first new treatment in a decade for this indication, demonstrating significantly improved progression-free survival. The combination reduced the risk of disease progression or death by 44% compared to the previous standard of care (THP), with a median progression-free survival exceeding three years.

**4. Rep. Gilbert Ray Cisneros, Jr. Buys AstraZeneca PLC (NASDAQ:AZN) Stock**
- Source: MarketBeat | 20251217T220952 | Somewhat-Bullish | Relevance: 100%
- Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 of AstraZeneca PLC (NASDAQ:AZN) stock on November 19th. This transaction was disclosed on December 15th and occurred in his "150 MAIN STREET TRUST > BANK OF AMERICA" account. AstraZeneca shares traded near $89.86 with a market capitalization of about $278.7 billion, and analysts currently hold a "Moderate Buy" rating with a consensus price target around $95.75.

**5. Sanders Morris Harris LLC Invests $950,000 in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251217T120952 | Bullish | Relevance: 100%
- Sanders Morris Harris LLC recently initiated a position in AstraZeneca PLC (NASDAQ:AZN), purchasing 12,379 shares valued at $950,000 in Q3. AstraZeneca reported strong Q3 earnings, surpassing analyst expectations with EPS of $1.19 and revenue of $15.19 billion, reflecting a 12% year-over-year increase. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $95.75.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $280.9B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.6 |
| Current P/E | 19.7 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). RSI neutral at 54. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.24% (CS: 53) | Neutral |
| RSI_14 | 54.2 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.175x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $90.61
- **Stop Loss:** $87.57 (3.4% risk)
- **Target:** $93.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 312
- **Position Value:** $28,270.32
- **Portfolio %:** 28.27%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*